Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy

Area of Science:

• Oncology
• Immunology
• Geriatrics

Background:

• Immune checkpoint blockade (ICB) therapies have revolutionized cancer treatment.
• The impact of patient age on ICB efficacy remains largely unknown.
• Understanding age-related differences is crucial for optimizing cancer immunotherapy.

Purpose of the Study:

• To investigate age-based differences in ICB treatment efficacy across various cancer types.
• To compare molecular profiles related to immunotherapy response between elderly and young patients.
• To identify age-biased immune characteristics influencing treatment outcomes.

Main Methods:

• Meta-analysis of published clinical trials using the deft approach.
• Comparison of immunotherapy-related molecular profiles from public trials and The Cancer Genome Atlas (TCGA).
• Validation of findings in independent datasets across 27 cancer types.

Main Results:

• No significant difference in ICB efficacy between elderly and young patients, except for melanoma patients receiving anti-PD-1 therapy.
• Elderly patients showed higher response rates and better prognosis in specific cancers like melanoma.
• Discovered divergent age-biased immune profiling, including tumor and immune cell features, in a pancancer setting.

Conclusions:

• ICB efficacy may vary by cancer type and be influenced by tumor-intrinsic and microenvironmental factors.
• Elderly patients exhibit distinct mutational properties in many cancer types, suggesting potential benefits from immune function modulation.
• Further research is needed to explore targeted immunotherapies for elderly cancer patients.